514 related articles for article (PubMed ID: 30376740)
1. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
Lee YS; Johnson DE; Grandis JR
Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
[No Abstract] [Full Text] [Related]
2. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
4. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
5. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A; Burtness B
Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
Moreira J; Tobias A; O'Brien MP; Agulnik M
Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
[TBL] [Abstract][Full Text] [Related]
8. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
9. Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z; Grandis JR; Johnson DE
Expert Opin Emerg Drugs; 2022 Sep; 27(3):333-344. PubMed ID: 36131561
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for head and neck cancer.
Wen Y; Grandis JR
Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
[TBL] [Abstract][Full Text] [Related]
11. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
[TBL] [Abstract][Full Text] [Related]
14. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
15. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Sola AM; Johnson DE; Grandis JR
Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
[TBL] [Abstract][Full Text] [Related]
16. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
Devaraja K
Pharmaceut Med; 2019 Aug; 33(4):269-289. PubMed ID: 31933185
[TBL] [Abstract][Full Text] [Related]
17. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
20. Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer.
Tathineni P; Joshi N; Jelinek MJ
Curr Treat Options Oncol; 2023 Jun; 24(6):680-692. PubMed ID: 37067660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
